Saniona ABSTU:30S +0.88%61 EBITDA Margin % is -1,107.36% as of Mar. 2026. GuruFocus rates STU:30S with a GF Score™ of 61/100 and a GF Value™ of €2.44 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 944 Biotechnology companies, Saniona AB ranks better than 95.55% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Saniona AB's EBITDA for the
three
months ended in Mar. 2026 was €-4.82 Mil. Saniona AB's Revenue for the
three
months ended in Mar. 2026 was €0.44 Mil. Therefore, Saniona AB's EBITDA margin for the quarter that ended in Mar. 2026 was -1,107.36%.
Saniona AB (STU:30S) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Saniona AB EBITDA Margin % Related Terms
Saniona AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Saniona AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:30S vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Saniona AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Saniona AB EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Saniona AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Saniona AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Saniona AB (STU:30S) has a EBITDA Margin % of -1,107.36% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Saniona AB and its competitors. According to the industry distribution chart, Saniona AB ranks #42 out of 944 companies in the Biotechnology industry, placing it in the top 4.4%.
Is Saniona AB's EBITDA Margin % too high?
Saniona AB's current EBITDA Margin % is -1,107.36%. Based on the distribution chart, Saniona AB ranks #42 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Saniona AB has a GF Score™ of 61/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Saniona AB's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Saniona AB ranks #42 out of 944 companies for EBITDA Margin %. This places Saniona AB in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Saniona AB and its competitors. Saniona AB's current EBITDA Margin % is -1,107.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Saniona AB stock overvalued right now?
Based on GuruFocus' analysis, Saniona AB (STU:30S) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.44, compared to a current price of €1.14 — trading 53.2% below its estimated fair value. The current EBITDA Margin % is -1,107.36%. Saniona AB's overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Saniona AB (STU:30S), the current EBITDA Margin % is -1,107.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Saniona AB (STU:30S) Overvalued in 2026?
Based on GuruFocus' analysis, Saniona AB stock appears to be undervalued.
The current stock price of €1.14 is trading 53.2% below its estimated GF Value™ of €2.44.
GuruFocus considers Saniona AB to be Significantly Undervalued.
Key valuation signals for STU:30S:
EBITDA Margin %: -1,107.36%
GF Value™: €2.44 vs. price of €1.14 (53.2% below fair value)
No single metric tells the full story. See the STU:30S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Saniona AB researches and develops drugs for the treatment of diseases of the central nervous system, autoimmune diseases, metabolic diseases, and the treatment of pain. It develops a technology platform that enables the investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors, and potassium channels. The company product pipeline includes Tesomet, SAN711, Tesofensine, SAN903, and SAN2219. Geographically, it operates in USA, Sweden, Germany, Denmark, and United Kingdom, out of which it derives maximum revenue from USA.
61GF Score
Get the complete analysis for STU:30S
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:30S has been successfully added to your 
